,127,128 Further studies are needed to support the initiation of ARNi, rather than ACE inhibitors/ARBs, as the first-line therapy in patients with advanced NYHA functional class IV HF or in post-MI patients with LV dysfunction. This evidence concerns the gene ACE and myocardial infarction.